MAP2 and Alzheimer disease: Small molecule inhibitors of EGF (Erlotinib) and FGF (PD173074) receptors in combination prevented the growth of the AI phenotype in small tumors (5 mm) and resulted in tumors primarily containing the AD phenotype (Nestin + MAP2+) irrespective of the AD or AI phenotype inoculated (Figure 10D).